Allscripts Healthcare Solutions
The 10-second takeaway
For the quarter ended Sep. 30 (Q3), Allscripts Healthcare Solutions missed estimates on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue dropped slightly and GAAP earnings per share dropped significantly.
Margins shrank across the board.
Allscripts Healthcare Solutions tallied revenue of $360.7 million. The 18 analysts polled by S&P Capital IQ expected to see sales of $377.0 million on the same basis. GAAP reported sales were 2.2% lower than the prior-year quarter's $368.8 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.23. The 20 earnings estimates compiled by S&P Capital IQ forecast $0.22 per share. GAAP EPS of $0.05 for Q3 were 55% lower than the prior-year quarter's $0.11 per share.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 43.5%, 180 basis points worse than the prior-year quarter. Operating margin was 5.6%, 670 basis points worse than the prior-year quarter. Net margin was 2.6%, 310 basis points worse than the prior-year quarter.
Next quarter's average estimate for revenue is $387.5 million. On the bottom line, the average EPS estimate is $0.26.
Next year's average estimate for revenue is $1.50 billion. The average EPS estimate is $0.76.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 445 members out of 473 rating the stock outperform, and 28 members rating it underperform. Among 110 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 104 give Allscripts Healthcare Solutions a green thumbs-up, and six give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Allscripts Healthcare Solutions is hold, with an average price target of $11.68.
- Add Allscripts Healthcare Solutions to My Watchlist.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.